Arends Alexandria M, Perez Anne, Wilder Christina, Jacob Seethal A
Riley Hospital for Children at Indiana University Health (AMA, SAJ), Indianapolis, IN.
Center for Pediatric and Adolescent Comparative Effectiveness Research (SAJ), Indiana University, Indianapolis, IN.
J Pediatr Pharmacol Ther. 2022;27(4):312-315. doi: 10.5863/1551-6776-27.4.312. Epub 2022 May 9.
Vaso-occlusive crisis (VOC) is the most common problem reported by patients with sickle cell disease (SCD). The objective of this study was to evaluate the impact of individualized pain plans in pediatric patients with SCD admitted for VOC.
This was a pre- and post-study of patients with SCD admitted to Riley Hospital for Children for VOC from July 1, 2019, through July 1, 2020. The primary outcome was length of inpatient stay for VOC. Secondary outcomes included final pain score, days on scheduled opioids, days on breakthrough opioids, and average morphine milligram equivalents (MME) used per day.
Nine patients were included. The mean age was 16 years (range, 10-20 years). Key clinical findings were decreases in median [IQR] for final pain scores (7 [4.5-9] vs 6 [2.5-8], p = 0.396) and number of days of breakthrough opioid use (5 [3-8] vs 4 [2.5-5.5], p = 0.233). Following implementation of an individualized pain plan, there was an increase in median average MME per day (65.94 [53.1-97.7] vs 82.85 [41-114.3], p = 0.844). Median length of stay and days on scheduled opioids remained the same.
This study demonstrated that use of individualized pain plans in a small population of patients with SCD might result in decreased pain scores and decreased days on breakthrough opioids.
血管闭塞性危机(VOC)是镰状细胞病(SCD)患者报告的最常见问题。本研究的目的是评估个性化疼痛计划对因VOC入院的小儿SCD患者的影响。
这是一项对2019年7月1日至2020年7月1日因VOC入住莱利儿童医院的SCD患者进行的前后对照研究。主要结局是VOC的住院时间。次要结局包括最终疼痛评分、使用常规阿片类药物的天数、使用突破性阿片类药物的天数以及每天使用的平均吗啡毫克当量(MME)。
纳入9例患者。平均年龄为16岁(范围10 - 20岁)。关键临床发现是最终疼痛评分的中位数[四分位间距]降低(7[4.5 - 9]对6[2.5 - 8],p = 0.396)以及突破性阿片类药物使用天数减少(5[3 - 8]对4[2.5 - 5.5],p = 0.233)。实施个性化疼痛计划后,每天平均MME的中位数增加(65.94[53.1 - 97.7]对82.85[41 - 114.3],p = 0.844)。住院时间中位数和使用常规阿片类药物的天数保持不变。
本研究表明,在一小部分SCD患者中使用个性化疼痛计划可能会降低疼痛评分并减少突破性阿片类药物的使用天数。